“Wilson’s Disease (WD) – Market”

DelveInsight’s ‘Wilson’s Disease (WD) – Market Insights, Epidemiology, and Market Forecast – 2032’ report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of WD in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The WD market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted Wilson’s disease market size from 2019 to 2032, segmented by seven major markets. The report also covers the current Wilson’s disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Some of the key facts of the Wilson’s Disease Market:

• Assessments as per DelveInsight’s analysts showed that there were more than 500 cases with Hepatic manifestation, around 200 cases with Neurologic manifestation, more than 100 Neuro-hepatic cases, and around 100 cases with other manifestations of WD in France in 2021. DelveInsight estimates that the prevalence of these manifestations will increase by 2032.

• Assessments as per DelveInsight’s analysts showed that in Japan, the highest cases of WD were found to be symptomatic which is around 2000 cases; whereas asymptomatic cases were around 300 in 2021. as per our assessments, symptoms-specific cases of WD are expected to increase by 2032.

Got queries? Click here to know more about the Wilson’s Disease Market Landscape 

Wilson’s Disease Overview 

Wilson’s disease (WD) is a genetic disorder that prevents the body from removing extra copper, causing copper to build up in the liver, brain, eyes, and other organs. Without treatment, high copper levels can cause life-threatening organ damage. WD is caused by mutations in the ATP7B gene, which is responsible for transporting copper from intracellular chaperone proteins into the secretory pathway, both for excretion into bile and for incorporation into apo-ceruloplasmin for the synthesis of functional ceruloplasmin. This defect results in progressive toxic accumulation of copper in the liver that begins in infancy when copper-containing solids are introduced into the diet.Clinical signs and symptoms of the disease may vary considerably, but the most common are hepatic (including cirrhosis), neurologic, and psychiatric disorders; ophthalmic signs (Kayser–Fleischer rings); and episodes of hemolysis coexisting with acute liver failure. Clinically asymptomatic siblings of WD patients are effectively identified by genetic testing.

Common signs of associated liver disease include a yellow discoloration (jaundice) of the skin, mucous membranes and the membranes (sclera) that line the eye, swelling (edema) of the legs and abdomen (ascites) due to abnormal retention of fluid, presence of abnormal blood vessels in the esophagus that may bleed (esophageal varices), a tendency for bruising and prolonged bleeding, and excessive tiredness (fatigue). The diagnostic approach is based on a complex set of clinical findings from patient history, physical examination, laboratory, and imaging diagnostic testing. Moreover, screening is recommended for anyone with a sibling, cousin, or parent with WD for early diagnosis

Wilson’s Disease Epidemiological Insight:

• According to the data published by National Organization for Rare Disorders (NORD), Wilson’s disease occurs in approximately one in 30,000 to 40,000 people worldwide.

• According to the research study published by Wijayasiri et al. (2021), it was observed that the clinical prevalence of Wilson’s disease in the UK was observed to be 15.5 per million i.e. 1/64,516. However, the clinical prevalence in this study was marked to be lower than the estimated prevalence of the UK.

• In 2021, the prevalent population of Wilson’s Disease in the United States was found to be approximately 9,000 cases which as per DelveInsight’s estimates, will increase by 2032.

• Assessments as per DelveInsight’s analysts revealed that there were about 1,200 cases with Hepatic manifestation, about 500 cases with Neurologic manifestation, more than 300 Neuro-hepatic cases, and around 400 cases with other manifestations of WD in the United States in 2021. DelveInsight estimates that the prevalence of these manifestations will increase by 2032.

• According to DelveInsight’s estimates in the year 2021, in Germany there was around 900 WD diagnosed cases which are expected to increase by 2032.

Wilson’s Disease Epidemiological Segmentation

• Total Wilson’s Disease prevelant cases
• Total Wilson’s Disease prevelant cases based on clinical manifestation 
• Total Wilson’s Disease diagnosed cases 
• Total Wilson’s Disease prevelant cases based on symptoms 

Wilson’s Disease Market Outlook 

The Wilson’s disease (WD) market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Wilson’s disease (WD) market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

This segment gives a thorough detail of Wilson’s disease (WD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Learn more by requesting for sample @ Wilson’s Disease Market Trends

Wilson’s Disease Key Companies  

• Orphalan
• AstraZeneca
• Vivet Therapeutics
• Pfizer
• Ultragenyx Pharmaceutical
• And many more 

Table of Contents

• Key Insights 
• Report Introduction 
• Executive Summary of Wilson’s Disease Market 
• Disease Background and Overview
• Epidemiology and patient population
• The United States 
• EU 5
• Wilson’s Disease Market  Emerging Therapies
• Wilson’s Disease Market Outlook
•  Market Access and Reimbursement of Therapies
•  Appendix
• Wilson’s Disease Market Report Methodology
• DelveInsight Capabilities
• Disclaimer
• About DelveInsight

Click here to read more about Wilson’s Disease Market Insights 

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/